MCID: HPT019
MIFTS: 56

Hepatic Encephalopathy malady

Categories: Rare diseases, Neuronal diseases, Liver diseases

Aliases & Classifications for Hepatic Encephalopathy

Aliases & Descriptions for Hepatic Encephalopathy:

Name: Hepatic Encephalopathy 12 50 52 14 69
Portal-Systemic Encephalopathy 12
Encephalopathy, Hepatic 50
Hepatoencephalopathy 50

Classifications:



External Ids:

Disease Ontology 12 DOID:13413
ICD10 33 K72
ICD9CM 35 572.2
MeSH 42 D006501
NCIt 47 C79596
UMLS 69 C0019151

Summaries for Hepatic Encephalopathy

NIH Rare Diseases : 50 hepatic encephalopathy is a syndrome observed in some patients with cirrhosis. it is defined as a spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, when other known brain disease has been excluded. signs and symptoms may be debilitating, and they can begin mildly and gradually, or occur suddenly and severely. they may include personality or mood changes, intellectual impairment, abnormal movements, a depressed level of consciousness, and other symptoms. there are several theories regarding the exact cause, but development of the condition is probably at least partially due to the effect of substances that are toxic to nerve tissue (neurotoxic), which are typically present with liver damage and/or liver disease. treatment depends upon the severity of mental status changes and upon the certainty of the diagnosis. last updated: 6/22/2016

MalaCards based summary : Hepatic Encephalopathy, also known as portal-systemic encephalopathy, is related to alcoholic hepatitis and meningitis. An important gene associated with Hepatic Encephalopathy is TSPO (Translocator Protein), and among its related pathways/superpathways are Immune response IL-23 signaling pathway and Circadian entrainment. The drugs Lactulose and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is characterized by loss of brain function, the occurrence of confusion, altered level of consciousness, and coma that results when the liver is unable to remove toxins from the blood.

Wikipedia : 71 Hepatic encephalopathy (HE) is the occurrence of confusion, altered level of consciousness, and coma as... more...

Related Diseases for Hepatic Encephalopathy

Diseases related to Hepatic Encephalopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
id Related Disease Score Top Affiliating Genes
1 alcoholic hepatitis 31.9 F2 IL6 TNF
2 meningitis 29.2 IL6 SLC17A5 TNF
3 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations 12.2
4 combined oxidative phosphorylation deficiency 1 11.6
5 hepatic coma 11.3
6 acute liver failure 11.1
7 hepatitis 10.9
8 encephalopathy 10.9
9 3-hydroxyacyl-coa dehydrogenase deficiency 10.8
10 congenital extrahepatic portosystemic shunt 10.8
11 hepatorenal syndrome 10.8
12 congenital dyserythropoietic anemia 10.3 ALB TNF
13 nondystrophic myotonia 10.3 ALB F2
14 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.3 IL6 TNF
15 dyslexia 5 10.3 IL6 TNF
16 duane retraction syndrome 10.2 ALB F2 TSPO
17 aortic atherosclerosis 10.2 IL6 TNF
18 degenerative disc disease 10.2 IL6 TNF
19 freiberg's disease 10.2 ALB F2
20 mikulicz disease 10.2 ALB IL6 TNF
21 plummer's disease 10.2 ALB IL6 TNF
22 chordoid meningioma 10.2 ALB IL6 TNF
23 choroiditis 10.2 ALB IL6 TNF
24 shoulder impingement syndrome 10.2 ALB IL6
25 ischemic optic neuropathy 10.2 ALB F2 IL6
26 rift valley fever 10.2 ALB IL6 TNF
27 mansonelliasis 10.2 ALB IL6 TNF
28 colon adenocarcinoma 10.2 ALB IL6 TNF
29 anterior foramen magnum meningioma 10.2 ALB IL6 TNF
30 supraumbilical midabdominal raphe and facial cavernous hemangiomas 10.2 F2 IL6
31 liver cirrhosis 10.2
32 familial nephrotic syndrome 10.2 ALB IL6 TNF
33 ebstein anomaly 10.2 SLC17A5 SLC25A13
34 autoimmune disease of central nervous system 10.2 F2 IL6 TNF
35 nephropathy with pretibial epidermolysis bullosa and deafness 10.2 ALB IL6 TNF
36 lichen disease 10.2 IL6 MAOA TNF
37 atrophy of prostate 10.2 F2 IL6 TNF
38 foodborne botulism 10.2 ALB IL6 TNF
39 congenital chloride diarrhea 10.2 ALB F2 IL6
40 pigmentation disease 10.2 ALB IL6 TNF
41 familial progressive hyperpigmentation 10.2 F2 GPT
42 uterine ligament clear cell adenocarcinoma 10.2 ALB IL6 TNF
43 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 10.2 ALB IL6 TNF
44 uterus interstitial leiomyoma 10.2 ALB F2 TNF
45 pulmonary eosinophilia 10.2 ALB IL6 TNF
46 migraine with aura 10.2 IL6 SLC17A5 TNF
47 gastric neuroendocrine tumor type 1 10.2 GPT SLC17A5
48 obstructive jaundice 10.2 ALB F2 TNF
49 acute chest syndrome 10.2 ALB IL6 TNF
50 tuberculoid leprosy 10.2 F2 MAOA MAOB

Comorbidity relations with Hepatic Encephalopathy via Phenotypic Disease Network (PDN): (show all 26)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Chronic Kidney Failure
Decubitus Ulcer Deficiency Anemia
Encephalopathy Esophageal Varix
Heart Disease Hepatitis
Hepatocellular Carcinoma Hepatorenal Syndrome
Hypersplenism Liver Disease
Neutropenia Portal Hypertension
Portal Vein Thrombosis Primary Biliary Cirrhosis
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Urea Cycle Disorder

Graphical network of the top 20 diseases related to Hepatic Encephalopathy:



Diseases related to Hepatic Encephalopathy

Symptoms & Phenotypes for Hepatic Encephalopathy

MGI Mouse Phenotypes related to Hepatic Encephalopathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.11 F2 GLS GLUL IL6 MAOA MAOB
2 homeostasis/metabolism MP:0005376 10.07 ALB F2 GC GLUL IL6 MAOA
3 cellular MP:0005384 9.97 SLC17A5 SLC1A2 TNF TSPO ALB GLUL
4 liver/biliary system MP:0005370 9.7 ALB GLUL IL6 NOS1 SLC25A13 TNF
5 mortality/aging MP:0010768 9.7 ALB F2 GLS GLUL IL6 NOS1
6 nervous system MP:0003631 9.28 F2 GLUL IL6 MAOA MAOB NOS1

Drugs & Therapeutics for Hepatic Encephalopathy

Drugs for Hepatic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 355)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1 4618-18-2 11333
2
Metformin Approved Phase 4 657-24-9 14219 4091
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
6
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
7
Propranolol Approved, Investigational Phase 4,Phase 3 525-66-6 4946
8
Magnesium oxide Approved Phase 4 1309-48-4 14792
9
Colchicine Approved Phase 4 64-86-8 6167 2833
10
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
11
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
12
Norfloxacin Approved Phase 4,Phase 3 70458-96-7 4539
13
Midodrine Approved Phase 4,Phase 2,Phase 3 133163-28-7, 42794-76-3 4195
14
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
15
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
16
Diphenhydramine Approved Phase 4 58-73-1, 147-24-0 3100
17
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
18
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
19
Promethazine Approved Phase 4 60-87-7 4927
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
22
Lamivudine Approved, Investigational Phase 4,Phase 2 134678-17-4 60825
23
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
24
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
25
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
26
Oxcarbazepine Approved Phase 4 28721-07-5 34312
27
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
28
Tolvaptan Approved Phase 4,Phase 3,Phase 2 150683-30-0 216237
29
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
30
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
31
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
32
Tranexamic Acid Approved Phase 4 1197-18-8 5526
33
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
34 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Hypoglycemic Agents Phase 4
36 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Excitatory Amino Acid Agonists Phase 4,Phase 3,Phase 2
38 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
40 N-Methylaspartate Phase 4,Phase 3,Phase 2,Phase 1
41 Adjuvants, Anesthesia Phase 4
42 Anesthetics Phase 4,Phase 2,Phase 1
43 Anesthetics, General Phase 4
44 Anesthetics, Intravenous Phase 4
45 Anti-Anxiety Agents Phase 4
46 Central Nervous System Depressants Phase 4,Phase 2
47 GABA Agents Phase 4,Phase 1,Phase 2
48 GABA Modulators Phase 4,Phase 1,Phase 2
49 Hypnotics and Sedatives Phase 4,Phase 2
50 Psychotropic Drugs Phase 4

Interventional clinical trials:

(show top 50) (show all 294)
id Name Status NCT ID Phase
1 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4
2 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4
3 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4
4 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4
5 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4
6 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4
7 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4
8 Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Unknown status NCT01059396 Phase 4
9 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
10 Study of Long-Term Peg Intron Vs. Colchicine in Non-Responders. Unknown status NCT00179413 Phase 4
11 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4
12 Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Completed NCT02158182 Phase 4
13 Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy Completed NCT00955500 Phase 4
14 Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy Completed NCT01559519 Phase 4
15 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4
16 Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4
17 Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate Completed NCT01847651 Phase 4
18 Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis Completed NCT00886925 Phase 4
19 Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4
20 The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy Completed NCT01842581 Phase 4
21 L-ornithine L-aspartate in Overt Hepatic Encephalopathy Completed NCT01722578 Phase 4
22 Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
23 Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation Completed NCT00839358 Phase 4
24 Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention Completed NCT01542801 Phase 4
25 Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" Completed NCT01201720 Phase 4
26 Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects Completed NCT01846455 Phase 4
27 Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection Completed NCT00662545 Phase 4
28 Growth Hormone and Glucose Metabolism Completed NCT00929799 Phase 4
29 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed NCT00640159 Phase 4
30 Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures Completed NCT00275925 Phase 4
31 Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures Completed NCT00275912 Phase 4
32 Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Recruiting NCT01846663 Phase 4
33 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4
34 PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4
35 Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS Recruiting NCT02925975 Phase 4
36 Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients Recruiting NCT02849132 Phase 4
37 Ramelteon for Treatment of Insomnia in Cirrhosis Recruiting NCT03091738 Phase 4
38 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Recruiting NCT02757170 Phase 4
39 Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Recruiting NCT02190357 Phase 4
40 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites Recruiting NCT02755701 Phase 4
41 Steroids in Fulminant Hepatic Failure in the Pediatric Age Group Recruiting NCT02375867 Phase 4
42 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
43 Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles Recruiting NCT01733199 Phase 4
44 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Not yet recruiting NCT03077217 Phase 4
45 Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding Not yet recruiting NCT03023189 Phase 4
46 Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load Not yet recruiting NCT02308319 Phase 4
47 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients(REPAIRS) Not yet recruiting NCT02484027 Phase 4
48 Quality of Life and Nutritional Improvements in Cirrhotic Patients Terminated NCT01842113 Phase 4
49 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4
50 Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury Terminated NCT01824589 Phase 4

Search NIH Clinical Center for Hepatic Encephalopathy

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Hepatic Encephalopathy

Anatomical Context for Hepatic Encephalopathy

MalaCards organs/tissues related to Hepatic Encephalopathy:

39
Liver, Brain, Testes, Cortex, Cerebellum, Endothelial, Prefrontal Cortex

Publications for Hepatic Encephalopathy

Articles related to Hepatic Encephalopathy:

(show top 50) (show all 747)
id Title Authors Year
1
Covert Hepatic Encephalopathy: Can My Patient Drive? ( 28027071 )
2017
2
Hepatic Encephalopathy. ( 28079343 )
2017
3
Hepatic Encephalopathy. ( 28079344 )
2017
4
Hepatic Encephalopathy. ( 28069286 )
2017
5
Nitrosative Stress-Induced Disruption of Baroreflex Neural Circuits in a Rat Model of Hepatic Encephalopathy: A DTI Study. ( 28079146 )
2017
6
Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. ( 28092641 )
2017
7
Hepatic Encephalopathy. ( 28076712 )
2017
8
Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. ( 28070704 )
2017
9
The Effects of Probiotics and Symbiotics on Risk Factors for Hepatic Encephalopathy: A Systematic Review. ( 28059938 )
2017
10
A Minimal hepatic encephalopathy in cirrhosis- how long to treat? ( 28051800 )
2017
11
A Observational cohort study of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS). ( 28051803 )
2017
12
Nitric oxide mediates effects of acute, not chronic, naltrexone on LPS-induced hepatic encephalopathy in cirrhotic rats. ( 28044452 )
2017
13
Clinical scenarios for the use of S100I^ as a marker of hepatic encephalopathy. ( 27158209 )
2016
14
Management of Hepatic Encephalopathy: A Primer. ( 27126547 )
2016
15
Letter: stepwise diagnosis in covert hepatic encephalopathy - do not forget ammonia. ( 27634234 )
2016
16
Brain edema: a valid endpoint for measuring hepatic encephalopathy? ( 27272740 )
2016
17
Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy. ( 27182210 )
2016
18
Probiotics in management of hepatic encephalopathy. ( 27121846 )
2016
19
Being an informal caregiver for a relative with liver cirrhosis and overt hepatic encephalopathy: a phenomenological study. ( 27167534 )
2016
20
Current state of knowledge of hepatic encephalopathy (part IV): Management of Hepatic Encephalopathy by liver support systems. ( 28013444 )
2016
21
Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in Population Study. ( 27639806 )
2016
22
Changes in the Microbiome in Cirrhosis and Relationship to Complications: Hepatic Encephalopathy, Spontaneous Bacterial Peritonitis, and Sepsis. ( 27997972 )
2016
23
Do branched chain amino acids improve hepatic encephalopathy in cirrhosis? ( 28024140 )
2016
24
Aphasia in a patient with acute hepatic encephalopathy associated with multifocal cortical brain lesions. ( 27157523 )
2016
25
Electroencephalogram variability in patients with cirrhosis associates with the presence and severity of hepatic encephalopathy. ( 27184531 )
2016
26
Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy. ( 27154504 )
2016
27
Fractalkine suppression during hepatic encephalopathy promotes neuroinflammation in mice. ( 27561705 )
2016
28
CLIF-SOFA score and SIRS are independent prognostic factors in patients with hepatic encephalopathy due to alcoholic liver cirrhosis. ( 27367990 )
2016
29
Letter: Stepwise diagnosis in covert hepatic encephalopathy-do not forget ammonia. Authors' reply. ( 27634235 )
2016
30
Low-light-level therapy as a treatment for minimal hepatic encephalopathy: behavioural and brain assessment. ( 27488510 )
2016
31
Hepatic encephalopathy (HE) due to intrahepatic portosystemic shunt after total gastrectomy. ( 27103358 )
2016
32
Hyperammonemia Is Associated with Increasing Severity of Both Liver Cirrhosis and Hepatic Encephalopathy. ( 27847646 )
2016
33
The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial. ( 27582881 )
2016
34
Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure. ( 27651377 )
2016
35
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. ( 27089005 )
2016
36
Hemodiafiltration for hepatic encephalopathy induced by Budd-Chiari syndrome in a patient with end-stage kidney disease. ( 28508963 )
2016
37
The brain gets its say: Hepatic encephalopathy and its evolving role in transplant priority. ( 27509240 )
2016
38
Rifaximin for the prevention of readmissions for patients with hepatic encephalopathy - the price is right. ( 27507251 )
2016
39
Hepatic Encephalopathy due to Congenital Multiple Intrahepatic Portosystemic Venous Shunts Successfully Treated by Percutaneous Transhepatic Obliteration. ( 27990104 )
2016
40
Can Testing the Impact of Minimal Hepatic Encephalopathy on Driving Skills be Prolific to Translate Research to Real Life Clinical Medicine? ( 27194888 )
2016
41
Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis. ( 28018114 )
2016
42
Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides. ( 27638474 )
2016
43
Status epilepticus in patients with cirrhosis: How to avoid misdiagnosis in patients with hepatic encephalopathy. ( 28092846 )
2016
44
Hepatic encephalopathy: A call to action to optimize patient outcomes. ( 27133209 )
2016
45
Cytokine levels contribute to the pathogenesis of minimal hepatic encephalopathy in patients with hepatocellular carcinoma via STAT3 activation. ( 26757951 )
2016
46
Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy. ( 27339764 )
2016
47
Abnormal cortical synaptic plasticity in minimal hepatic encephalopathy. ( 27475415 )
2016
48
Natural History of Patients Taking Rifaximin-I+ for Recurrent Hepatic Encephalopathy and Risk of Future Overt Episodes and Mortality: A Post-hoc Analysis of Clinical Trials Data. ( 27136714 )
2016
49
Abnormalities of voxel-based whole-brain functional connectivity patterns predict the progression of hepatic encephalopathy. ( 27138528 )
2016
50
Evaluation of Cognitivity, Proinflammatory Cytokines, and Brain MRI in Minimal Hepatic Encephalopathy induced by Cirrhosis and EHPVO. ( 27119420 )
2016

Variations for Hepatic Encephalopathy

Expression for Hepatic Encephalopathy

LifeMap Discovery
Genes differentially expressed in tissues of Hepatic Encephalopathy patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 PSPH phosphoserine phosphatase Brain - 4.35 0.000
Search GEO for disease gene expression data for Hepatic Encephalopathy.

Pathways for Hepatic Encephalopathy

Pathways related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.38 F2 IL6 NOS1 TNF
2
Show member pathways
12.1 GLS GLUL MAOA MAOB NOS1 SLC1A2
3
Show member pathways
12.04 ALB F2 IL6 TNF
4 11.81 IL6 NOS1 TNF
5
Show member pathways
11.77 NOS1 SLC1A2 TNF
6 11.76 IL6 MAOA TNF
7 11.59 GLS GLUL MAOA
8
Show member pathways
11.3 MAOA MAOB NOS1
9
Show member pathways
11.13 MAOA NOS1 TNF
10
Show member pathways
11.05 GLS GLUL GPT
11 10.88 GLS GLUL GPT
12 10.85 IL6 TNF
13 10.66 MAOA MAOB
14
Show member pathways
10.64 MAOA MAOB
15
Show member pathways
10.59 MAOA MAOB
16
Show member pathways
10.43 GLS GLUL GPT NOS1
17
Show member pathways
10.34 GLUL SLC1A2

GO Terms for Hepatic Encephalopathy

Cellular components related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.17 GLS GLUL MAOA MAOB NOS1 SLC25A13

Biological processes related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.76 IL6 MAOB SLC1A2 TSPO
2 cellular response to lipopolysaccharide GO:0071222 9.67 IL6 TNF TSPO
3 response to wounding GO:0009611 9.5 F2 IL6 SLC1A2
4 positive regulation of chemokine production GO:0032722 9.48 IL6 TNF
5 L-glutamate transmembrane transport GO:0089711 9.43 SLC1A2 SLC25A13
6 L-glutamate transport GO:0015813 9.4 SLC1A2 SLC25A13
7 neurotransmitter catabolic process GO:0042135 9.37 MAOA MAOB
8 negative regulation of lipid storage GO:0010888 9.26 IL6 TNF
9 dopamine catabolic process GO:0042420 9.16 MAOA MAOB
10 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 8.96 IL6 TNF
11 cellular amino acid biosynthetic process GO:0008652 8.8 GLS GLUL GPT

Molecular functions related to Hepatic Encephalopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 L-glutamate transmembrane transporter activity GO:0005313 8.96 SLC1A2 SLC25A13
2 primary amine oxidase activity GO:0008131 8.62 MAOA MAOB

Sources for Hepatic Encephalopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....